AxoGen (AXGN) Set to Release Quarterly Earnings on Wednesday

AxoGen (NASDAQ:AXGN) is expected to be posting its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect AxoGen to announce earnings of $0.1340 per share and revenue of $73.18 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. The business had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. On average, analysts expect AxoGen to post ($0.44) EPS for the current fiscal year and $0.09 EPS for the next fiscal year.

AxoGen Trading Up 2.6%

Shares of NASDAQ:AXGN opened at $36.17 on Wednesday. AxoGen has a 52-week low of $16.78 and a 52-week high of $52.91. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -53.19 and a beta of 1.17. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. The business has a 50-day moving average price of $43.95 and a 200-day moving average price of $42.09.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $55.00 target price on shares of AxoGen in a research report on Wednesday, July 29th. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Raymond James Financial raised their price target on shares of AxoGen from $48.00 to $53.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Wall Street Zen cut shares of AxoGen from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.73.

Insider Buying and Selling

In other news, Director Amy Wendell sold 13,353 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the completion of the transaction, the director owned 107,976 shares of the company’s stock, valued at $5,228,197.92. The trade was a 11.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $47.34, for a total value of $3,195,450.00. Following the completion of the sale, the executive vice president owned 50,135 shares in the company, valued at $2,373,390.90. The trade was a 57.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 98,503 shares of company stock valued at $4,656,947 over the last quarter. 2.44% of the stock is currently owned by company insiders.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.